Lessons from Past Enforcement Actions: Protecting Your License When Exploring New Agents

History offers useful lessons for owners considering involvement with new compounds like retatrutide. Previous enforcement waves around compounded medications consistently show several patterns:

• Regulators eventually focus on both suppliers and the clinics that use products that have been flagged.
• Documentation and structural clarity become critical once scrutiny increases.
• Practices that maintained strong compliance processes before enforcement intensified generally fared better than those that operated more informally.

The most effective protection comes from proactive, well-documented decision-making. This includes clear policies on which compounds the practice will consider, formal review processes before offering any new agent, robust informed consent, and appropriate use of research frameworks when dealing with investigational substances.

From a business perspective, these same practices also protect practice value. Buyers and their advisors look for evidence of thoughtful risk management, especially around newer or higher-scrutiny compounds.

The lessons from past enforcement actions are consistent: proactive documentation, structural clarity, and conservative decision-making around new agents protect both professional licenses and long-term practice value.

Related reading: FDA Warning Letters on Retatrutide · M&A Advisory · Compounding Pharmacy Due Diligence